Hold Rating on Moderna Amid Uncertain Near-Term Revenue from Pandemic Influenza ...

Retrieved on: 2025-01-21 16:55:21

Tags for this article:

Click the tags to see associated articles and topics

Hold Rating on Moderna Amid Uncertain Near-Term Revenue from Pandemic Influenza .... View article details on hiswai:

Excerpt

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price tar.

Article found on: markets.businessinsider.com